<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343366</url>
  </required_header>
  <id_info>
    <org_study_id>DUHS/DR-O/2017/266</org_study_id>
    <nct_id>NCT03343366</nct_id>
  </id_info>
  <brief_title>Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy</brief_title>
  <official_title>Glycemic Control in Type-2 Diabetes Mellitus Patients Through Non-Surgical Periodontal Therapy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dow University of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The idea of &quot;Mouth-Body Connection&quot; has recently been introduced, according to which oral
      health is considered as a vital constituent of general health; like-wise many systemic
      disorders have oral manifestations. Recently it is submitted that incident and prevalent
      chronic periodontal infection, known as chronic periodontitis (CP) possibly has a causal
      relationship with diabetes mellitus (DM) having effects on HbA1c, fasting plasma/ blood
      glucose (FPG/ FBG) and fasting plasma/ blood insulin (FPI/ FBI) levels. Experimental research
      has suggested that treating CP may improve glycemic control and insulin resistance in
      Non-Insulin Dependent Type-2 DM patients (T2DM). However, there is limited data concerning
      the need and effects of adjunct antibiotic therapy (AAT) along with scaling root planning
      (SRP) in treating CP for long lasting results. Therefore, it is suggested that further
      research with larger samples must be undertaken for a successful periodontal therapy that may
      help improve glycemic control at desired levels and longer durations. This study is designed
      to evaluate effects of periodontal therapy [SRP, metronidazole (MET) and oral hygiene
      instructions (OHI)] through three-arm trial experiment comprising of SRP+MET+OHI, SRP+OHI and
      OHI+ Delayed Therapy (DT) groups on HbA1c, FPG, FPI levels and Insulin Resistance calculated
      through Homeostasis Model Assessment (HOMA-IR) to fill research gap. This study will target
      around 1000 patients with CP screened for T2DM at selected Periodontal Clinics of Dow
      University dental hospitals to recruit 150 participants randomly allocated in each group (50
      in each group). Post-therapy follow-up results will be assessed at 1, 3 and 6 months to
      evaluate short and long term changes in status of CP, FPG, FPI and HbA1c.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall evidence that CP has a role in the causal pathway of DM is yet limited and
      inconsistent. Although intervention research has suggested that treating CP may improve
      glycemic control and insulin resistance in Type-2 DM patients; yet there is limited data
      concerning the effects of adjunct antibiotic therapy (AAT) in addition to scaling root
      planning (SRP) in treating CP for long lasting results. Therefore, it is suggested that
      further research with bigger samples must be undertaken for a successful periodontal therapy
      that may help improve glycemic control at desired levels and long durations.

      This study is designed to evaluate the effects of periodontal therapy [SRP, metronidazole
      (MET) and oral hygiene instructions (OHI)] through a three-arm trial comprising of
      SRP+MET+OHI group, SRP+OHI group and OHI+ Delayed Therapy (DT) group, on HbA1c, FPG, FPI
      levels and Insulin Resistance calculated through Homeostasis Model Assessment (HOMA-IR) to
      fill the research gap.

      A parallel group, single blind three-arm design randomized controlled trial (RCT) will be
      conducted over a period of approximately 2 years.

      More than 1000 patients will be screened for CP with T2DM to recruit 150 participants for the
      study. They will be randomly allocated in each group (with 50 in each group). Post-therapy
      follow-up will be for 1, 3 and 6 months to evaluate short term and long term changes in
      status of CP, FPG, FPI and HbA1c respectively.

      Structured screening form will be used to collect baseline information. HbA1c, FPG levels and
      IL will be recorded at standardized lab, whereas, CP will be evaluated using standardized
      periodontal indices by calibrated examiners.

      Stata version 11.0 will be used for all kind of data management. Descriptive analysis will be
      performed using frequency percentages of the categorical variables whereas, mean (standard
      deviation) will be calculated for all continuous study variables. Inferential statistics will
      include Chi-square test to assess proportional differences of the categorical variables
      between the three interventional groups. Whereas, one-way Analysis of Variance test (ANOVA)
      will be used to evaluate the mean differences of the continuous variables in three different
      groups. McNemar's Chi-square and Repeated Measure Analysis of Variance (RMANOVA) will be used
      to assess differences in categorical and continuous variables respectively over time for each
      intervention group; and particularly to assess second secondary study objective. For insulin
      resistance HOMA-IR will be calculated to assess an association between CP and insulin
      resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This multi-centric randomized controlled trial (RCT) will be conducted on the baseline sample derived from periodontal clinics of dental institutes of Dow University of Health Sciences. More than 1000 patients will be screened to recruit 150 calculated sample participants (with 50 in each group) with reference to 0.7%, 0.6% reduction and no reduction (0.06%) in the baseline mean HbA1c over a period of 3 months among SRP+AAT, SRP Only and no treatment groups respectively(48) the calculated sample size is 35 in each group (1:1:1) with 99% power of test and 99% confidence interval. Adding 40% dropout rate expected over 6-months follow-up, 49 participants in each group will be required that will be rounded off to 50 in each group (with a ratio of 1:1:1).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>A parallel group, single blind three-arm design randomized controlled trial (RCT) will be conducted. The examiners, both for periodontal examination and laboratory investigations will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated Hemoglobin (HbA1c)</measure>
    <time_frame>Change from baseline (0) to 3 months and 6 months post intervention</time_frame>
    <description>To examine effects of three non-surgical periodontal therapies through change in HbA1c levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Periodontal Measure 1</measure>
    <time_frame>Change at 1 and 3 months post intervention in all three groups</time_frame>
    <description>To examine the changes in clinical periodontal measures in terms of Clinical Attachment Loss(CAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Periodontal Measure 2</measure>
    <time_frame>Change at 1 and 3 months post intervention in all three groups</time_frame>
    <description>To examine the changes in clinical periodontal measures in terms of Periodontal Pocket Depth (PPD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Periodontal Measure 3</measure>
    <time_frame>Change at 1 and 3 months post intervention in all three groups</time_frame>
    <description>To examine the changes in clinical periodontal measures in terms of probing (BOP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG)</measure>
    <time_frame>at 3 and 6 month follow-up between groups.</time_frame>
    <description>To identify an association of clinical periodontal changes on FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Insulin (FPI) levels</measure>
    <time_frame>at 3 and 6 month follow-up between groups.</time_frame>
    <description>To identify an association of clinical periodontal changes on FPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>at 3 and 6 month follow-up between groups.</time_frame>
    <description>To identify an association of clinical periodontal changes on insulin resistance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Periodontitis</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Test Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in this group will receive a combination of ultrasonic scaling and hand instrumentation required for planing of the root surfaces (SRP) followed by systemic AAT followed by routine warm salt water rinses for 3-5 days and OHI. SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth. Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days. OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants in this group will receive a combination of Scaling Root Planing followed by routine warm salt water rinses for 3-5 days and OHI. Same procedure for SRP and OHI will be followed as that followed in Test Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants in this group will receive only routine warm salt water rinses for 3-5 days and Oral Hygiene Instructions as that followed in Test Group 1 and Test Group 2. However, after completing six (6) months of evaluation they will be provided DT either in the form of SRP+MET or SRP only in addition to OHI, whichever would be found to have a significant beneficial effect on CP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days</description>
    <arm_group_label>Test Group 1</arm_group_label>
    <other_name>Systemic Adjunct Antibiotic Therapy (AAT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Scaling Root Planing</intervention_name>
    <description>SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.</description>
    <arm_group_label>Test Group 1</arm_group_label>
    <arm_group_label>Test Group 2</arm_group_label>
    <other_name>SRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Oral Hygiene Instructions</intervention_name>
    <description>OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.</description>
    <arm_group_label>Test Group 1</arm_group_label>
    <arm_group_label>Test Group 2</arm_group_label>
    <arm_group_label>Control Group 3</arm_group_label>
    <other_name>OHI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 35 to 65 years patients suffering from moderate to severe CP at baseline
             and having HbA1c level â‰¥7% and &lt;10% at baseline with already diagnosed T2DM at least
             an year ago will be included as study sample. Moreover, those currently under oral
             glycemic therapy, having at least 16 natural teeth for the entire study duration and
             not under any definitive periodontal treatment since last 6 months of baseline visit
             will be considered as inclusion criteria along with no oral soft tissue lesions and
             those willing to sign informed consent will be considered to be recruited for this
             trial

        Exclusion Criteria:

          -  Pregnant or breast feeding women

          -  Gestational Diabetes

          -  Patients currently receiving dialysis

          -  Patients with cardiac pacemakers

          -  Alcoholic

          -  Patients with any serious concurrent disease or complication with &lt;1 year of life
             expectancy.

          -  Patients suffering from myelo-proliferating disorder (such as sickle cell disease) or
             under any such treatment that promotes a shift in the hemoglobin pattern.

          -  Under any anti-inflammatory drugs (daily for &gt;7 consecutive days) within last 2 months
             of baseline visit, other than low dose aspirin prescribed for Cardio-vascular disease

          -  Under any systemic immunosuppressive drugs like corticosteroids, cyclosporine etc.

          -  Under any systemic antibiotics for &gt;7 consecutive days within last four weeks of
             baseline visit.

          -  No medication for oral problems during last one month and during follow-up period that
             may affect interventions and HbA1c levels

          -  Any change in diabetes related medications in last 3 months of baseline visit, such as
             change in dose of any one hyperglycemic drug therapy by more than two-fold, addition
             or subtraction of an oral hypoglycemic agent or addition of insulin.

          -  Patients requiring any surgical (such as flap-surgery) or any non-surgical periodontal
             care that is restricted throughout study period depending upon the participants' group
             he/she may belong to.

          -  Patients with a history of night-grinding/ bruxism

          -  Patients with a history of allergic reaction with metronidazole

          -  Patients with mentally or/ and gross physical disability

          -  Failure to liaise on with the study protocol over the next 6 months

          -  With drawl from participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Ambrina Qureshi Head of the Department Community Dentistry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dow University of Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Head of the Department Community Dentistry</last_name>
    <phone>+922199232660</phone>
    <phone_ext>4063</phone_ext>
    <email>ambrina.qureshi@duhs.edu.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vice Principal Dow International Medical College</last_name>
    <phone>+922199232660</phone>
    <phone_ext>4035</phone_ext>
    <email>z.haque@duhs.edu.pk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dow University of Health Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sind</state>
        <zip>00000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ambrina Qureshi, PhD Scholar</last_name>
      <phone>+922199232660</phone>
      <phone_ext>4063</phone_ext>
      <email>ambrina.qureshi@duhs.edu.pk</email>
    </contact>
    <contact_backup>
      <last_name>Zeba Haque, PhD</last_name>
      <phone>+922199232660</phone>
      <phone_ext>4035</phone_ext>
      <email>z.haque@duhs.edu.pk</email>
    </contact_backup>
    <investigator>
      <last_name>Ambrina Qureshi, M.Phil</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeba Haque, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Syed Akhtar Hussain Bukhari, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akhtar Ali Baloch, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dow University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Ambrina Qureshi</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>fasting plasma glucose</keyword>
  <keyword>fasting plasma insulin</keyword>
  <keyword>HOMA-IR insulin resistance</keyword>
  <keyword>clinical attachment loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

